+

PL2590993T3 - Polipeptydy - Google Patents

Polipeptydy

Info

Publication number
PL2590993T3
PL2590993T3 PL11743207T PL11743207T PL2590993T3 PL 2590993 T3 PL2590993 T3 PL 2590993T3 PL 11743207 T PL11743207 T PL 11743207T PL 11743207 T PL11743207 T PL 11743207T PL 2590993 T3 PL2590993 T3 PL 2590993T3
Authority
PL
Poland
Prior art keywords
polypeptides
Prior art date
Application number
PL11743207T
Other languages
English (en)
Inventor
Caroline Ekblad
Lars Abrahmsén
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of PL2590993T3 publication Critical patent/PL2590993T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL11743207T 2010-07-09 2011-07-08 Polipeptydy PL2590993T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39928510P 2010-07-09 2010-07-09
US40356110P 2010-09-17 2010-09-17
PCT/EP2011/061623 WO2012004384A2 (en) 2010-07-09 2011-07-08 Polypeptides
EP20110743207 EP2590993B1 (en) 2010-07-09 2011-07-08 Polypeptides

Publications (1)

Publication Number Publication Date
PL2590993T3 true PL2590993T3 (pl) 2015-10-30

Family

ID=44630120

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11743207T PL2590993T3 (pl) 2010-07-09 2011-07-08 Polipeptydy
PL15165722T PL2933262T3 (pl) 2010-07-09 2011-07-08 Polipeptydy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15165722T PL2933262T3 (pl) 2010-07-09 2011-07-08 Polipeptydy

Country Status (22)

Country Link
US (3) US9211344B2 (pl)
EP (2) EP2933262B1 (pl)
JP (2) JP5827994B2 (pl)
KR (1) KR101884654B1 (pl)
CN (3) CN110437320B (pl)
AU (1) AU2011275766B2 (pl)
BR (1) BR112013000452A2 (pl)
CA (1) CA2804002C (pl)
DK (2) DK2933262T3 (pl)
ES (2) ES2540114T3 (pl)
HK (2) HK1209761A1 (pl)
IL (1) IL223989B (pl)
LT (1) LT2933262T (pl)
MX (1) MX2013000314A (pl)
MY (1) MY161679A (pl)
NO (1) NO2933262T3 (pl)
NZ (1) NZ604805A (pl)
PL (2) PL2590993T3 (pl)
RU (1) RU2577964C2 (pl)
TR (1) TR201809437T4 (pl)
WO (1) WO2012004384A2 (pl)
ZA (1) ZA201300994B (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
PL2590993T3 (pl) 2010-07-09 2015-10-30 Affibody Ab Polipeptydy
DK2621515T3 (en) 2010-09-28 2017-07-17 Aegerion Pharmaceuticals Inc Chimeric seal-human leptin polypeptide with increased solubility
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
JP6276202B2 (ja) 2012-02-20 2018-02-07 スウェディッシュ・オーファン・バイオヴィトラム・アーベー(ペーウーベーエル) ヒト補体c5に結合するポリペプチド
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
WO2013143890A1 (en) 2012-03-28 2013-10-03 Affibody Ab Oral administration
EP2900688B1 (en) * 2012-09-25 2017-02-22 Affibody AB Albumin binding polypeptide
EP2904013B1 (en) 2012-10-05 2018-11-07 Affibody AB Her3 binding polypeptides
WO2014064237A1 (en) 2012-10-25 2014-05-01 Affibody Ab Abd binding polypeptide
WO2014064238A1 (en) * 2012-10-25 2014-05-01 Affibody Ab Method for the separation of proteins containing an albumin-binding
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
WO2014076177A1 (en) * 2012-11-14 2014-05-22 Affibody Ab New polypeptide
WO2014096163A1 (en) * 2012-12-19 2014-06-26 Affibody Ab New polypeptides
CN105246503A (zh) 2013-03-14 2016-01-13 第一三共株式会社 Pcsk9的新颖结合蛋白
EP2970406B1 (en) * 2013-03-15 2017-12-13 Affibody AB New polypeptides
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015028550A1 (en) 2013-08-28 2015-03-05 Affibody Ab C5 binding polypeptides
RU2020128977A (ru) * 2013-08-28 2021-11-30 Сведиш Орфан Биовитрум Аб (Пабл) Стабильные полипептиды, связывающиеся с с5 комплемента человека
EP3038642A4 (en) 2013-08-30 2017-01-18 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015091957A1 (en) * 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide
MX384363B (es) 2014-05-22 2025-03-14 Pieris Pharmaceuticals Gmbh Nuevos polipéptidos de unión específica y usos de los mismos.
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
MX386297B (es) 2014-09-29 2025-03-18 Univ Duke Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
WO2016064817A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2016208161B2 (en) 2015-01-12 2020-01-16 Affibody Ab IL-17A-binding polypeptides
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
MY179505A (en) * 2015-04-02 2020-11-09 Molecular Partners Ag Recombinant binding proteins and their use
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
IL271920B2 (en) 2017-07-11 2024-03-01 Alexion Pharma Inc Polypeptides that bind to the C5 component or serum albumin and their fusion proteins
US11077199B2 (en) 2017-08-09 2021-08-03 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
CN108362873B (zh) * 2018-02-13 2021-06-01 苏州仁端生物医药科技有限公司 一种镉离子检测试剂盒及其应用
EP3765496A1 (en) 2018-03-13 2021-01-20 Affibody AB Polypeptides based on a novel scaffold
CA3150442A1 (en) 2019-09-02 2021-03-11 Biotest Ag Factor viii protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
WO2021089695A1 (en) 2019-11-05 2021-05-14 Affibody Ab Polypeptides
CN114929261A (zh) 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
EP3878515A1 (en) 2020-03-09 2021-09-15 Hober Biotech AB Therapeutic agent targeting her2
KR20230123989A (ko) 2020-12-21 2023-08-24 애피바디 에이비 신규 폴리펩티드
WO2022171892A1 (en) 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
CN113416683B (zh) * 2021-06-01 2023-05-02 南昌大学 一种大肠杆菌Nissle 1917基因工程菌及其制备方法和应用
CN118632866A (zh) 2022-02-08 2024-09-10 阿菲博迪公司 结合胸腺基质淋巴细胞生成素的蛋白质z变体及其医疗用途
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
WO2024227930A1 (en) 2023-05-04 2024-11-07 Affibody Ab New polypeptide
WO2024263059A1 (ru) * 2023-06-21 2024-12-26 Общество С Ограниченной Ответственностью "Герофарм" Гибридные белки-предшественники пептидных иммуногенов ‒ компонентов вакцины против covid-19
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6362225B1 (en) 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US7288265B1 (en) 2000-10-16 2007-10-30 Lectec Corporation Treating viral infection at smallpox vaccination site
NZ527173A (en) * 2000-12-29 2006-03-31 Savient Pharmaceuticals Inc Specific human antibodies for selective cancer therapy
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
WO2005097202A2 (en) 2004-04-06 2005-10-20 Affibody Ab Use of serum albumin binding peptides conjugates for the preparation of a medicament
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
EP2769990A3 (en) * 2004-12-02 2015-02-25 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
EP2032605A2 (en) * 2006-05-24 2009-03-11 Bayer Schering Pharma Aktiengesellschaft HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
CN101646689A (zh) * 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
AU2007306340A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
CA2694139C (en) * 2007-07-31 2018-06-05 Affibody Ab Albumin binding polypeptide compositions
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
NZ588603A (en) 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
CN101294178A (zh) 2008-05-26 2008-10-29 江南大学 一种用两阶段培养法提高发酵生产透明质酸产量的方法
CN101294187B (zh) * 2008-06-06 2013-07-31 暨南大学 一种缓释生物活性多肽的方法与应用
US9186412B2 (en) 2008-08-18 2015-11-17 Entera Bio Ltd. Methods and compositions for oral administration of insulin
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
PL2590993T3 (pl) 2010-07-09 2015-10-30 Affibody Ab Polipeptydy
WO2012016043A2 (en) 2010-07-29 2012-02-02 The Regents Of The University Of Michigan Portable, wireless multi-channel impedance analyzer
DK2621515T3 (en) 2010-09-28 2017-07-17 Aegerion Pharmaceuticals Inc Chimeric seal-human leptin polypeptide with increased solubility
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
WO2013143890A1 (en) 2012-03-28 2013-10-03 Affibody Ab Oral administration
EP2900688B1 (en) 2012-09-25 2017-02-22 Affibody AB Albumin binding polypeptide
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide

Also Published As

Publication number Publication date
US20190375799A1 (en) 2019-12-12
WO2012004384A3 (en) 2012-03-29
KR101884654B1 (ko) 2018-08-02
MX2013000314A (es) 2013-01-29
US9211344B2 (en) 2015-12-15
ES2540114T3 (es) 2015-07-08
NO2933262T3 (pl) 2018-09-29
AU2011275766B2 (en) 2015-10-22
KR20130034043A (ko) 2013-04-04
US10329331B2 (en) 2019-06-25
US20140162956A1 (en) 2014-06-12
RU2013102953A (ru) 2014-08-20
DK2933262T3 (en) 2018-06-25
JP2016053047A (ja) 2016-04-14
CN110437320B (zh) 2023-10-20
LT2933262T (lt) 2018-07-10
MY161679A (en) 2017-05-15
PL2933262T3 (pl) 2018-10-31
BR112013000452A2 (pt) 2020-02-11
EP2933262B1 (en) 2018-05-02
RU2577964C2 (ru) 2016-03-20
CN103003296A (zh) 2013-03-27
AU2011275766A1 (en) 2013-01-10
IL223989B (en) 2018-10-31
JP5827994B2 (ja) 2015-12-02
NZ604805A (en) 2014-09-26
US20160108095A1 (en) 2016-04-21
TR201809437T4 (tr) 2018-07-23
CA2804002C (en) 2021-07-20
ZA201300994B (en) 2020-05-27
JP6486810B2 (ja) 2019-03-20
EP2933262A1 (en) 2015-10-21
CN110437320A (zh) 2019-11-12
ES2676403T3 (es) 2018-07-19
CN110437321A (zh) 2019-11-12
WO2012004384A2 (en) 2012-01-12
JP2013534421A (ja) 2013-09-05
CA2804002A1 (en) 2012-01-12
HK1209761A1 (en) 2016-04-08
EP2590993A2 (en) 2013-05-15
HK1182719A1 (en) 2013-12-06
EP2590993B1 (en) 2015-05-06
DK2590993T3 (en) 2015-06-29

Similar Documents

Publication Publication Date Title
HK1209761A1 (en) Polypeptides
RS59462B1 (sr) Polipeptidi
DK3342786T3 (en) Anti-dll3-antistof
AP3107A (en) 5-Alkynyl-pyrimidines
ZA201309174B (en) Polypeptides
IL222301A0 (en) Protease-activatable pore-forming polypeptides
EP2566479A4 (en) AZA-INDAZOLES
EP2640189A4 (en) 3-deutero-pomalidomide
HK1181747A1 (zh) -肟基- -苯基-丙烷類
DK3466977T3 (en) Anti-vla-4-antistoffer
GB201012651D0 (en) Peptides
EP2641891A4 (en) PKC ACTIVATOR-
GB201018480D0 (en) Factors
GB201016494D0 (en) Polypeptide
AU4536P (en) TB01 Tibouchina urvilleana
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4937P (en) FlatinsulGL Myoporum insulare
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
PT2718316T (pt) Polipeptídeos
GB201003906D0 (en) Binding polypeptides
GB201008108D0 (en) Helisuacer III
GB201005840D0 (en) Multi-catch pro
GB201003907D0 (en) Detecting polypeptides
AU2010278V (en) Little Tuffy Lomandra confertifolia
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载